Iterum Therapeutics plc (ITRM)
| Market Cap | 10.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -56.33M |
| Shares Out | 13.04M |
| EPS (ttm) | -4.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,134 |
| Open | 0.720 |
| Previous Close | 0.695 |
| Day's Range | 0.670 - 0.833 |
| 52-Week Range | 0.601 - 2.050 |
| Beta | 1.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2023 |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. [Read more]
Financial Performance
Financial StatementsNews
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
-- Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 -- -- Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (N...
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics to Present Data at ASM Microbe 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics Reports First Quarter 2023 Financial Results
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a cli...
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- -Registration Trial for uUTI Ongoing and On Track- - - -Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET--
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Reports Employment Inducement Grant
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next genera...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next ge...
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024--
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25 years--
Iterum Therapeutics to Present Data at IDWeek 2022
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation or...
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024--
Iterum Therapeutics Shares Are Surging - Read Why
Iterum Therapeutics plc (NASDAQ: ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulope...
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022--
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
Iterum Therapeutics Reports First Quarter 2022 Financial Results
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024-
Iterum Therapeutics Provides Regulatory Update
DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
- -Registration Trial for uUTI Planned in Second Half of 2022- - - -Cash Runway into 2024-- --Company to host conference call today at 8:30am ET--
Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next ge...
Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
- -Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem-- --Cash Runway into 2024-- --Iterum to host conference call tod...